Artificial Intelligence in Pulmonary Medicine and Critical Care: A Comprehensive Review of Current Applications, Challenges, and Future Directions

Abstract

Background: Artificial intelligence (AI) and machine learning (ML) technologies are rapidly transforming pulmonary medicine and critical care, offering unprecedented opportunities for improved diagnosis, prognosis, and patient management. The intensive care unit (ICU) generates vast amounts of real-time data, creating an ideal environment for AI applications, while pulmonary medicine benefits from advanced imaging analysis and predictive modeling.

Objective: This comprehensive review examines the current landscape of AI applications in pulmonary medicine and critical care, evaluating their clinical utility, performance metrics, implementation challenges, and future directions.

Methods: A systematic literature search was conducted in PubMed, Web of Science, Scopus, and the IEEE databases for studies published between 2020 and 2025, focusing on AI/ML applications in respiratory disease diagnosis, mechanical ventilation optimization, sepsis prediction, sleep medicine, pulmonary function test interpretation, and chronic respiratory disease management.

Results: AI systems demonstrate significant promise across multiple domains: lung cancer detection achieves over 90% sensitivity with reduced false positives by up to 30%; Acute Respiratory Distress Syndrome (ARDS) prediction models show pooled sensitivity of 0.81 and specificity of 0.82; sepsis prediction algorithms can alert clinicians up to 12 hours before clinical onset with AUC of 0.83; sleep apnea diagnosis using deep learning achieves 97% sensitivity for moderate-to-severe cases; and AI-based pulmonary function test interpretation achieves 86.6% diagnostic accuracy compared to 65.8% for pulmonologists. The FDA has authorized more than 950 AI-enabled medical devices, with pathology and radiology as major application areas.

Discussion: Despite promising performance metrics, significant barriers to clinical implementation persist. Model transparency remains a critical concern, as many algorithms function as "black boxes" unsuitable for high-stakes medical decisions. Validation studies are predominantly single-center and retrospective, limiting generalizability across diverse populations and healthcare settings. Regulatory frameworks are evolving, with the FDA's Predetermined Change Control Plans pathway and the EU AI Act establishing new compliance requirements. Workflow integration challenges, including alarm fatigue and IT infrastructure demands, must be addressed. Ethical considerations regarding data privacy, algorithmic bias, and liability for AI-assisted decisions require ongoing attention. Importantly, the deployment of AI must maintain a qualified human clinician as the final arbitrator of all diagnostic and therapeutic choices, ensuring that AI augments rather than replaces physician expertise. Future directions include multimodal data integration, federated learning for privacy-preserving research, and explainable AI approaches to enhance clinician trust within a supervised deployment framework.

Conclusions: AI technologies offer transformative potential for pulmonary medicine and critical care, though successful implementation requires addressing challenges including model transparency, workflow integration, regulatory compliance, and validation across diverse populations. Multi-center prospective trials are needed to establish clinical benefit and patient outcomes.